Next Article in Journal
A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP
Next Article in Special Issue
Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles
Previous Article in Journal
Induction of WNT16 via Peptide-mRNA Nanoparticle-Based Delivery Maintains Cartilage Homeostasis
Previous Article in Special Issue
Hyaluronate Nanoparticles as a Delivery System to Carry Neuroglobin to the Brain after Stroke
Open AccessArticle

PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study

1
Grupo de Investigación Ciencia de los Materiales, Instituto de Química, Facultad de Ciencias Exactas y Naturales, Universidad de Antioquia, Calle 62 No. 52–59, Medellín 050015, Colombia
2
Department of Life Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy
3
Department of Biomedical, Metabolic and Neural Science, University of Modena and Reggio Emilia, 41124 Modena, Italy
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(1), 72; https://doi.org/10.3390/pharmaceutics12010072
Received: 29 November 2019 / Revised: 10 January 2020 / Accepted: 14 January 2020 / Published: 17 January 2020
(This article belongs to the Special Issue Drug Delivery to the Brain)
The treatment of diseases that affect the central nervous system (CNS) represents a great research challenge due to the restriction imposed by the blood–brain barrier (BBB) to allow the passage of drugs into the brain. However, the use of modified nanomedicines engineered with different ligands that can be recognized by receptors expressed in the BBB offers a favorable alternative for this purpose. In this work, a BBB-penetrating peptide, angiopep-2 (Ang–2), was conjugated to poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles through pre- and post-formulation strategies. Then, their ability to cross the BBB was qualitatively assessed on an animal model. Proof-of-concept studies with fluorescent and confocal microscopy studies highlighted that the brain-targeted PLGA nanoparticles were able to cross the BBB and accumulated in neuronal cells, thus showing a promising brain drug delivery system. View Full-Text
Keywords: PLGA; PEG; PF127; angiopep-2; nanoparticles; blood–brain barrier PLGA; PEG; PF127; angiopep-2; nanoparticles; blood–brain barrier
Show Figures

Figure 1

MDPI and ACS Style

Hoyos-Ceballos, G.P.; Ruozi, B.; Ottonelli, I.; Da Ros, F.; Vandelli, M.A.; Forni, F.; Daini, E.; Vilella, A.; Zoli, M.; Tosi, G.; Duskey, J.T.; López-Osorio, B.L. PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study. Pharmaceutics 2020, 12, 72. https://doi.org/10.3390/pharmaceutics12010072

AMA Style

Hoyos-Ceballos GP, Ruozi B, Ottonelli I, Da Ros F, Vandelli MA, Forni F, Daini E, Vilella A, Zoli M, Tosi G, Duskey JT, López-Osorio BL. PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study. Pharmaceutics. 2020; 12(1):72. https://doi.org/10.3390/pharmaceutics12010072

Chicago/Turabian Style

Hoyos-Ceballos, Gina P.; Ruozi, Barbara; Ottonelli, Ilaria; Da Ros, Federica; Vandelli, Maria A.; Forni, Flavio; Daini, Eleonora; Vilella, Antonietta; Zoli, Michele; Tosi, Giovanni; Duskey, Jason T.; López-Osorio, Betty L. 2020. "PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study" Pharmaceutics 12, no. 1: 72. https://doi.org/10.3390/pharmaceutics12010072

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop